Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 VaccineGlobeNewsWire • 08/25/22
Dynavax Technologies (DVAX) Recently Broke Out Above the 20-Day Moving AverageZacks Investment Research • 08/08/22
How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 92%Zacks Investment Research • 08/08/22
Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva's Inactivated COVID-19 VaccineGlobeNewsWire • 08/01/22
Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022PRNewsWire • 07/21/22
Wall Street Analysts See an 111% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?Zacks Investment Research • 07/21/22
European Commission Approves Purchase Agreement Amendment for Valneva's Inactivated COVID-19 VaccineGlobeNewsWire • 07/20/22
Clover's COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous BoosterGlobeNewsWire • 06/27/22
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001GlobeNewsWire • 06/24/22
Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in EuropeGlobeNewsWire • 06/23/22
Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector VaccinesGlobeNewsWire • 06/14/22
Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001GlobeNewsWire • 06/10/22